Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

As a player in the growing telehealth sector, Hims & Hers Health ($HIMS) has grown significantly, driving its stock up over ...

Hims & Hers is a fantastic value despite its high on-the-surface P/E ratio and valuation metrics. Click here to read why HIMS ...

Subscriptions are needed to obtain prescription products and are created. A representative from Hims states that subscription plans are formatted to ship products out every 30, 90 or 180 days ...

Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...

Hims offers a wide variety of Viagra doses and other ED medications. Hims offers other health products and medications for conditions such as hair loss and premature ejaculation. Meetings with ...

Exploding sales of prescription weight loss medications have catapulted Novo Nordisk (NVO) and Eli Lilly (LLY) to become the ...

The GLP-1 hype has left the stock Hims & Hers is a consumer-facing telehealth company that offers medical consultations and prescribes medications and other products for various health-related ...

Hims & Hers Health Q3 2024 revenue projected to surpass estimates by $5M-$10M. Truist consumer survey shows 10% use compounded GLP-1 medications, while 14% prefer branded options. Thursday, The ...